Bicycle Therapeutics (NASDAQ:BCYC) Issues Earnings Results

Bicycle Therapeutics (NASDAQ:BCYC) issued its earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.25, FiscalAI reports. The company had revenue of $34.06 million for the quarter, compared to analyst estimates of $12.22 million. Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%.

Bicycle Therapeutics Stock Down 4.3%

Shares of BCYC stock traded down $0.17 on Friday, reaching $3.65. The stock had a trading volume of 238,871 shares, compared to its average volume of 423,310. Bicycle Therapeutics has a 12 month low of $3.33 and a 12 month high of $8.48. The firm’s 50-day moving average is $3.85 and its two-hundred day moving average is $4.60. The firm has a market capitalization of $255.82 million, a price-to-earnings ratio of -1.34 and a beta of 1.68.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Zacks Research downgraded shares of Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Needham & Company LLC lowered their target price on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Jefferies Financial Group restated a “buy” rating and issued a $10.00 price target on shares of Bicycle Therapeutics in a report on Thursday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Friday, October 2nd. Finally, Wall Street Zen upgraded Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $13.57.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.